- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Exagen Inc (XGN)"Exagen Inc stock price live, this page displays NASDAQ XGN stock exchange data. View the XGN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Exagen Inc real time stock price chart below.
What Is the Exagen Inc Stock Price Today?
The Exagen Inc stock price today is 5.775.
What Is the Stock Symbol for Exagen Inc?
The stock symbol for Exagen Inc is ""XGN.""
What Stock Exchange Does Exagen Inc Trade On?
Exagen Inc is listed and trades on the NASDAQ stock exchange.
Is Exagen Inc a Good Stock to Buy?
Determining whether Exagen Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the XGN quote. (ISIN: US30068X1037)"
What Is the Exagen Inc Stock Price Today?
The Exagen Inc stock price today is 5.775.
What Is the Stock Symbol for Exagen Inc?
The stock symbol for Exagen Inc is ""XGN.""
What Stock Exchange Does Exagen Inc Trade On?
Exagen Inc is listed and trades on the NASDAQ stock exchange.
Is Exagen Inc a Good Stock to Buy?
Determining whether Exagen Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the XGN quote. (ISIN: US30068X1037)"
5.775
+0.045(+0.87%)
Closed
After Hours
6.130+0.355(+6.147%)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
5.730
6.190
52 wk Range
1.300
6.210
XGN Scorecard
Full Analysis
3 analysts have revised their earnings upwards for the upcoming period
Unusual Post-Market activity
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
5.7306.190
52 wk Range
1.3006.210
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
XGN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
6.250
Upside
+8.225%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
RSI suggests the stock is in overbought territory
- Exagen stock soars to 52-week high, hits $3.79
- Investing.com
- Exagen stock soars to 52-week high, hits $4.97
- Investing.com
- Exagen stock soars to 52-week high, hits $4.97
- Investing.com
- Exagen stock soars to 52-week high, hits $3.79
- Investing.com
Exagen Inc Company Profile
Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient’s blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
Exagen Inc SWOT Analysis
Diagnostic Dominance | Exagen's AVISE CTD test drives impressive revenue growth, with Q1 2024 showing a 28% year-over-year increase and improved gross margins approaching 60% |
Strategic Expansion | Explore Exagen's plans to introduce new rheumatoid arthritis markers in Q4 2024, potentially enhancing diagnostic capabilities and market position |
Financial Trajectory | Analysts project positive outlook with price targets ranging from $5 to $7, reflecting confidence in Exagen's growth potential and market opportunities |
Navigating Challenges | Learn how Exagen addresses flat test volumes and competitive pressures while leveraging its strong cash position of $76.4 million to fuel growth initiatives |
XGN Full Pro Research
Institutional-Grade Stock Analysis
Understand how XGN earns money
Financial health at a glance
Bearish and bullish outlooks
Latest expert insights
Actionable Pro Tips, and many more...
Gain access to 1400+ in-depth research reports on the most popular US stocks
Exagen Inc Earnings Call Summary for Q4/2024
- Q3 revenue: $12.5M, YTD: $42M (+8% YoY). Full-year forecast: $55-56M. 45% ASP increase drives growth.
- Adjusted EBITDA loss improved 70% YoY. Net loss: $5M, down 40%. Operating expenses reduced to 83% of revenue from 101%.
- $22M cash balance. Cash flow positivity expected by end of 2025, supported by new biomarker launches.
- AVISE CTD test expanding from 23 to 28 markers. New RA markers to increase diagnosis accuracy from 70% to 85%.
- Capacity expansion plans include extended operating schedule and potential night shift to double capacity.
Last Updated: 2024/11/13, 00:08
Read Full TranscriptCompare XGN to Peers and Sector
Metrics to compare | XGN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipXGNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −6.0x | −0.5x | −0.6x | |
PEG Ratio | −0.13 | −0.01 | 0.00 | |
Price/Book | 7.9x | 0.8x | 2.6x | |
Price / LTM Sales | 1.8x | 6.6x | 3.2x | |
Upside (Analyst Target) | −0.2% | 349.4% | 49.4% | |
Fair Value Upside | Unlock | 13.5% | 7.8% | Unlock |
Analysts' Recommendations
5 Buy
1 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 6.250
(+8.23% Upside)
FAQ
What Is the Exagen (XGN) Stock Price Today?
The Exagen stock price today is 5.775
What Stock Exchange Does Exagen Trade On?
Exagen is listed and trades on the NASDAQ stock exchange.
What Is the Stock Symbol for Exagen?
The stock symbol for Exagen is "XGN."
What Is the Exagen Market Cap?
As of today, Exagen market cap is 101.86M.
What is Exagen Earnings Per Share?
The Exagen EPS is -0.938.
What Is the Next Exagen Earnings Date?
Exagen will release its next earnings report on 23 Mar 2025.
From a Technical Analysis Perspective, Is XGN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.